IRIS
RAVELLI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 46.506
AS - Asia 5.612
NA - Nord America 4.364
SA - Sud America 412
AF - Africa 109
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 57.014
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 45.512
US - Stati Uniti d'America 4.026
SG - Singapore 2.315
CN - Cina 1.342
VN - Vietnam 782
BD - Bangladesh 619
FR - Francia 447
BR - Brasile 248
HK - Hong Kong 189
CA - Canada 123
FI - Finlandia 117
DE - Germania 97
CH - Svizzera 75
MX - Messico 67
AR - Argentina 66
GB - Regno Unito 62
JP - Giappone 60
IN - India 52
JM - Giamaica 39
NL - Olanda 39
ID - Indonesia 38
ZA - Sudafrica 32
IQ - Iraq 30
CO - Colombia 27
PK - Pakistan 26
CR - Costa Rica 24
PH - Filippine 24
EC - Ecuador 22
TR - Turchia 20
RU - Federazione Russa 19
KE - Kenya 18
DZ - Algeria 17
ES - Italia 17
HN - Honduras 17
TH - Thailandia 16
VE - Venezuela 16
IE - Irlanda 14
CL - Cile 13
RO - Romania 12
SE - Svezia 12
JO - Giordania 11
MA - Marocco 11
PL - Polonia 11
PY - Paraguay 11
SV - El Salvador 11
PR - Porto Rico 10
GT - Guatemala 9
AU - Australia 8
KR - Corea 8
OM - Oman 8
TT - Trinidad e Tobago 8
UA - Ucraina 8
EG - Egitto 7
RS - Serbia 7
SA - Arabia Saudita 7
TN - Tunisia 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
DO - Repubblica Dominicana 6
HR - Croazia 6
NI - Nicaragua 6
AT - Austria 5
BY - Bielorussia 5
LT - Lituania 5
NP - Nepal 5
AL - Albania 4
IR - Iran 4
KZ - Kazakistan 4
MK - Macedonia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
AZ - Azerbaigian 3
BB - Barbados 3
BG - Bulgaria 3
BO - Bolivia 3
BS - Bahamas 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
ET - Etiopia 3
HU - Ungheria 3
IL - Israele 3
KW - Kuwait 3
MM - Myanmar 3
MY - Malesia 3
PE - Perù 3
SI - Slovenia 3
UY - Uruguay 3
UZ - Uzbekistan 3
BE - Belgio 2
CI - Costa d'Avorio 2
CY - Cipro 2
DM - Dominica 2
GA - Gabon 2
GE - Georgia 2
GM - Gambi 2
KH - Cambogia 2
LB - Libano 2
MD - Moldavia 2
PA - Panama 2
PT - Portogallo 2
Totale 56.982
Salva come PNG Salva come JPEG
Città #
Genova 27.207
Genoa 10.739
Rapallo 4.080
Vado Ligure 2.849
Singapore 1.139
San Jose 960
Ashburn 674
Lauterbourg 400
Ho Chi Minh City 231
Beijing 225
New York 213
Hanoi 181
Hong Kong 178
Santa Clara 126
Helsinki 112
Los Angeles 94
Council Bluffs 91
Bordighera 88
Frankfurt am Main 73
Zurich 70
Milan 60
Rome 48
Buffalo 46
Chicago 43
Tokyo 43
Dallas 37
Haiphong 37
Mexico City 35
Orem 34
Naples 33
Da Nang 32
Phoenix 30
Boardman 26
Montreal 25
Amsterdam 24
Toronto 24
Kingston 21
São Paulo 21
Atlanta 20
San José 20
Tianjin 20
Brooklyn 18
Houston 18
Newark 17
Washington 17
Florence 16
City of London 15
Johannesburg 15
Seattle 15
Chennai 14
Columbus 14
Cardiff 13
Charlotte 13
Nairobi 13
Philadelphia 13
Biên Hòa 12
Dublin 12
Guangzhou 12
Las Vegas 12
Louisville 12
Palermo 12
San Francisco 12
Turin 12
Baghdad 11
Catania 11
Denver 11
Hải Dương 11
Kansas City 11
Karachi 11
Miami 11
Queens 11
San Salvador 11
Shanghai 11
Des Moines 10
Nuremberg 10
Princeton 10
Rio de Janeiro 10
Bologna 9
Cincinnati 9
London 9
Memphis 9
New Delhi 9
Pasadena 9
Tegucigalpa 9
Amman 8
Bari 8
Cleveland 8
Jakarta 8
Quito 8
Santiago 8
Thái Nguyên 8
Berlin 7
Durham 7
Fayetteville 7
Istanbul 7
Medellín 7
Muscat 7
Orlando 7
Padua 7
Paris 7
Totale 51.048
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 273
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 271
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 240
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 238
Inactive disease and remission in childhood-onset systemic lupus erythematosus. 234
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. 228
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 220
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 216
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 215
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 214
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 211
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 210
Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. 209
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 206
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 206
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 205
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 204
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 202
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 201
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 201
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 201
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 201
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 201
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 199

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 197
Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. 195
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 195
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 193
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 192
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 192
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 191
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 190
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 189
Comparison of clinical versus ultrasound determined synovitis in juvenile idiopathic arthritis. 188
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 188
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 188
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 187
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 186
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 185
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 185
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 185
Advances in biomarkers for paediatric rheumatic diseases 183
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 182
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 182
Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. 182
Clinical outcome measures in juvenile idiopathic arthritis 181
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 181
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis? 179
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 177
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 177
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 177
Type I interferon pathway activation in COPA syndrome 175
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 174
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 174
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 173
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 173
Advances and challenges in imaging in juvenile idiopathic arthritis. 172
Preliminary definition of improvement in juvenile arthritis. 172
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 172
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 172
Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. 171
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 170
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 169
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 168
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 167
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 167
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 166
Antiphospholipid antibody syndrome in pediatric patients. 166
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 165
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 165
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 165
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 165
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 165
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 165
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 164
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 164
A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases 164
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 163
Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis 163
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 163
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 162
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 162
Criteria to define response to therapy in paediatric rheumatic diseases. 162
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 160
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 160
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 160
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 160
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 159
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 159
Recent therapeutic advances in juvenile idiopathic arthritis 159
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 159
Patterns of clinical remission in select categories of juvenile idiopathic arthritis 158
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 158
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence 157
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 157
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 157
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. 157
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. 157
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 157
Cytokines in juvenile rheumatoid arthritis. 156
Totale 18.281
Salva come PNG Salva come JPEG
Categoria #
all - tutte 195.810
article - articoli 192.306
book - libri 0
conference - conferenze 332
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.172
Totale 391.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.959 140 373 514 349 315 194 364 1.132 202 448 290 638
2022/20234.919 523 307 56 386 815 875 39 490 903 41 412 72
2023/20242.366 143 382 48 264 218 351 133 148 98 80 120 381
2024/20257.273 173 635 313 444 806 762 695 1.194 319 434 624 874
2025/202614.195 1.497 415 754 905 1.867 1.396 2.199 658 1.064 1.385 944 1.111
2026/20271.260 1.260 0 0 0 0 0 0 0 0 0 0 0
Totale 57.997